In a turbulent week for the IPO market, 17 IPOs and 20 SPACs went public, and one company postponed, defense contractor Leonardo DRS (DRS). While returns cooled off, with just over half of the week’s IPOs finishing below issue, there...read more
LAVA Therapeutics, a Dutch Phase 1/2a biotech developing gamma-delta T cell therapies for cancer, raised $101 million by offering 6.7 million shares at $15, within the range of $14 to $16. The company is focused on developing a platform of novel bispecific...read more
Updated Monday, 3/22. 15 IPOs are currently scheduled to raise $5.7 billion in the week ahead as IPO activity continues to pick up. The diverse group spans six sectors and includes cleaning products, defense technology, low-cost TVs, crafting...read more
LAVA Therapeutics, a Dutch Phase 1/2a biotech developing gamma-delta T cell therapies for cancer, announced terms for its IPO on Thursday. The Utrecht, Netherlands-based company plans to raise $101 million by offering 6.7 million shares at a price range of...read more
US IPO Weekly Recap: Healthcare shines in a 17 IPO week
In a turbulent week for the IPO market, 17 IPOs and 20 SPACs went public, and one company postponed, defense contractor Leonardo DRS (DRS). While returns cooled off, with just over half of the week’s IPOs finishing below issue, there...read more
Dutch cancer biotech LAVA Therapeutics prices US IPO at $15 midpoint
LAVA Therapeutics, a Dutch Phase 1/2a biotech developing gamma-delta T cell therapies for cancer, raised $101 million by offering 6.7 million shares at $15, within the range of $14 to $16. The company is focused on developing a platform of novel bispecific...read more
US IPO Week Ahead: Cleaning products, crafting machines, and more in a diverse 15 IPO week
Updated Monday, 3/22. 15 IPOs are currently scheduled to raise $5.7 billion in the week ahead as IPO activity continues to pick up. The diverse group spans six sectors and includes cleaning products, defense technology, low-cost TVs, crafting...read more
Dutch cancer biotech LAVA Therapeutics sets terms for $101 million US IPO
LAVA Therapeutics, a Dutch Phase 1/2a biotech developing gamma-delta T cell therapies for cancer, announced terms for its IPO on Thursday. The Utrecht, Netherlands-based company plans to raise $101 million by offering 6.7 million shares at a price range of...read more